![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AQP9 |
Gene summary for AQP9 |
![]() |
Gene information | Species | Human | Gene symbol | AQP9 | Gene ID | 366 |
Gene name | aquaporin 9 | |
Gene Alias | AQP-9 | |
Cytomap | 15q21.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | H0YK62 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
366 | AQP9 | NAFLD1 | Human | Liver | NAFLD | 7.77e-10 | 7.62e-01 | -0.04 |
366 | AQP9 | S41 | Human | Liver | Cirrhotic | 4.44e-02 | 3.01e-01 | -0.0343 |
366 | AQP9 | HCC1_Meng | Human | Liver | HCC | 2.93e-03 | -1.54e-01 | 0.0246 |
366 | AQP9 | HCC2_Meng | Human | Liver | HCC | 2.47e-02 | -1.55e-01 | 0.0107 |
366 | AQP9 | cirrhotic1 | Human | Liver | Cirrhotic | 4.57e-04 | -1.48e-01 | 0.0202 |
366 | AQP9 | HCC1 | Human | Liver | HCC | 6.30e-29 | 6.40e+00 | 0.5336 |
366 | AQP9 | HCC2 | Human | Liver | HCC | 3.59e-08 | 1.52e+00 | 0.5341 |
366 | AQP9 | HCC5 | Human | Liver | HCC | 8.89e-06 | 3.93e+00 | 0.4932 |
366 | AQP9 | Pt13.b | Human | Liver | HCC | 4.48e-04 | 5.36e-02 | 0.0251 |
366 | AQP9 | Pt14.b | Human | Liver | HCC | 4.68e-04 | 2.55e-01 | 0.018 |
366 | AQP9 | S014 | Human | Liver | HCC | 7.13e-20 | 1.24e+00 | 0.2254 |
366 | AQP9 | S015 | Human | Liver | HCC | 4.50e-05 | 1.30e+00 | 0.2375 |
366 | AQP9 | S016 | Human | Liver | HCC | 9.40e-25 | 1.61e+00 | 0.2243 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
GO:00100387 | Liver | NAFLD | response to metal ion | 62/1882 | 373/18723 | 5.05e-05 | 1.19e-03 | 62 |
GO:0015850 | Liver | NAFLD | organic hydroxy compound transport | 50/1882 | 284/18723 | 6.01e-05 | 1.32e-03 | 50 |
GO:00466837 | Liver | NAFLD | response to organophosphorus | 28/1882 | 131/18723 | 9.05e-05 | 1.82e-03 | 28 |
GO:00069703 | Liver | NAFLD | response to osmotic stress | 20/1882 | 84/18723 | 1.95e-04 | 3.41e-03 | 20 |
GO:00140747 | Liver | NAFLD | response to purine-containing compound | 29/1882 | 148/18723 | 3.34e-04 | 5.13e-03 | 29 |
GO:0015721 | Liver | NAFLD | bile acid and bile salt transport | 10/1882 | 30/18723 | 4.67e-04 | 6.74e-03 | 10 |
GO:00515917 | Liver | NAFLD | response to cAMP | 20/1882 | 93/18723 | 8.01e-04 | 9.95e-03 | 20 |
GO:001003812 | Liver | Cirrhotic | response to metal ion | 150/4634 | 373/18723 | 2.27e-11 | 1.37e-09 | 150 |
GO:001087611 | Liver | Cirrhotic | lipid localization | 147/4634 | 448/18723 | 6.24e-05 | 7.12e-04 | 147 |
GO:000686911 | Liver | Cirrhotic | lipid transport | 128/4634 | 398/18723 | 4.54e-04 | 3.69e-03 | 128 |
GO:005159112 | Liver | Cirrhotic | response to cAMP | 37/4634 | 93/18723 | 9.58e-04 | 6.78e-03 | 37 |
GO:000697011 | Liver | Cirrhotic | response to osmotic stress | 34/4634 | 84/18723 | 1.06e-03 | 7.40e-03 | 34 |
GO:001407411 | Liver | Cirrhotic | response to purine-containing compound | 53/4634 | 148/18723 | 1.70e-03 | 1.08e-02 | 53 |
GO:0046689 | Liver | Cirrhotic | response to mercury ion | 8/4634 | 13/18723 | 5.27e-03 | 2.70e-02 | 8 |
GO:004668311 | Liver | Cirrhotic | response to organophosphorus | 45/4634 | 131/18723 | 8.57e-03 | 3.97e-02 | 45 |
GO:001003822 | Liver | HCC | response to metal ion | 208/7958 | 373/18723 | 1.35e-07 | 2.56e-06 | 208 |
GO:001087621 | Liver | HCC | lipid localization | 228/7958 | 448/18723 | 1.80e-04 | 1.41e-03 | 228 |
GO:005159121 | Liver | HCC | response to cAMP | 57/7958 | 93/18723 | 1.96e-04 | 1.52e-03 | 57 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa049762 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
hsa0497611 | Liver | NAFLD | Bile secretion | 20/1043 | 89/8465 | 5.08e-03 | 4.43e-02 | 3.57e-02 | 20 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AQP9 | SNV | Missense_Mutation | novel | c.395C>T | p.Ala132Val | p.A132V | O43315 | protein_coding | deleterious(0.04) | possibly_damaging(0.643) | TCGA-EY-A1H0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |
AQP9 | SNV | Missense_Mutation | novel | c.211N>A | p.Ala71Thr | p.A71T | O43315 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AQP9 | SNV | Missense_Mutation | c.382C>A | p.Leu128Ile | p.L128I | O43315 | protein_coding | tolerated(0.72) | benign(0.019) | TCGA-49-4506-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
AQP9 | SNV | Missense_Mutation | novel | c.236C>T | p.Ser79Phe | p.S79F | O43315 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-55-1592-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
AQP9 | SNV | Missense_Mutation | novel | c.238G>T | p.Gly80Cys | p.G80C | O43315 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-8506-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AQP9 | SNV | Missense_Mutation | novel | c.176N>A | p.Thr59Asn | p.T59N | O43315 | protein_coding | deleterious(0.01) | probably_damaging(0.948) | TCGA-78-8640-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
AQP9 | SNV | Missense_Mutation | c.388T>A | p.Ser130Thr | p.S130T | O43315 | protein_coding | tolerated(0.28) | benign(0.015) | TCGA-86-6562-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | vinblastine | PD | |
AQP9 | SNV | Missense_Mutation | novel | c.639N>G | p.Cys213Trp | p.C213W | O43315 | protein_coding | tolerated(0.15) | probably_damaging(0.932) | TCGA-51-4080-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
AQP9 | SNV | Missense_Mutation | novel | c.545C>G | p.Ser182Cys | p.S182C | O43315 | protein_coding | deleterious(0.03) | possibly_damaging(0.886) | TCGA-56-7221-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
AQP9 | SNV | Missense_Mutation | rs374284559 | c.794N>C | p.Val265Ala | p.V265A | O43315 | protein_coding | deleterious(0.05) | benign(0.007) | TCGA-56-8628-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
366 | AQP9 | ION CHANNEL | HORMONES | 15647391 | ||
366 | AQP9 | ION CHANNEL | ANDROGENS | 12021052 | ||
366 | AQP9 | ION CHANNEL | TESTOSTERONE | TESTOSTERONE | 12021052,12002438 | |
366 | AQP9 | ION CHANNEL | ANTISERUM | 16035648 | ||
366 | AQP9 | ION CHANNEL | inhibitor | 178101032 | ||
366 | AQP9 | ION CHANNEL | FLUTAMIDE | FLUTAMIDE | 12021052 | |
366 | AQP9 | ION CHANNEL | CISPLATIN | CISPLATIN | 12396244 | |
366 | AQP9 | ION CHANNEL | UREA | UREA | 12594337 | |
366 | AQP9 | ION CHANNEL | inhibitor | 178101102 | PHLORETIN | |
366 | AQP9 | ION CHANNEL | DHT | ANDROSTANOLONE | 15850448 |
Page: 1 |